Convalescent Plasma
/ Rockefeller University
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 17, 2025
Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles.
(PubMed, J Clin Invest)
- ""Higher-risk" CCP units also mediated greater Fcγ receptor IIa signaling against cells expressing SARS-CoV-2 spike compared with "lower-risk" units. This study finds that post-transfusion activation of coagulation pathways during severe COVID-19 is associated with specific CCP antibody profiles and supports a potential mechanism of immune complex-activated coagulopathy."
Journal • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 24, 2024
Convalescent Plasma for Covid-19-Induced ARDS.
(PubMed, N Engl J Med)
- No abstract available
Journal • Infectious Disease • Novel Coronavirus Disease
December 20, 2022
Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study.
(PubMed, EBioMedicine)
- "Overall, CCP exhibited moderately increased inflammatory markers compared to the control plasma with no discernible differences in ex-vivo bioactivity. Auto-Abs to type I IFNs detected in a small fraction of CCP were not associated with reported adverse events or differences in inflammatory markers. Additional studies, including careful clinical evaluation of patients treated with CCP, are required in order to further define the clinical relevance of these findings."
IO biomarker • Journal • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • IL10 • IL6 • TNFA
June 29, 2022
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
(PubMed, BMC Infect Dis)
- P2/3 | "CP was not associated with viral load reduction, despite the early increase in IgG anti-SARS-CoV-2 antibodies. However, CP is safe and could be a therapeutic option to reduce the hospital length of stay. Trial registration NCT04332835."
Clinical • Journal • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1